BPC-157 vs GHK-Cu: Which Heals What?
Here is how these two compounds compare — based on published research, not marketing claims.
BPC-157
212
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
GHK-Cu
186
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
These two peptides both appear in conversations about healing and regeneration. But they work on completely different levels. BPC-157 is studied for internal tissue repair — tendons, gut lining, ligaments. GHK-Cu is a copper-binding tripeptide studied for skin, collagen production, and surface-level wound healing. Choosing between them depends on what you are trying to repair.
Key Differences
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Evidence Level | Human Trials | Animal Studies |
| Category | Body Protection Compound | Copper Peptide |
| Human Data | Limited but growing. Two pilot studies in humans. Over 200 animal studies form the primary evidence base. PSI rates this L3 based on human pilot data and strong animal evidence. | A few small human studies focused on skin applications. Most evidence is in vitro (cell culture) and animal models. Less clinical depth than BPC-157. |
| Safety Profile | Extensive animal safety data with no reported toxicity at therapeutic doses. Two human pilot studies published (2024-2025) with no serious adverse events. Not FDA-approved. | Well-tolerated in topical applications. Limited safety data for injectable use. Generally considered low-risk based on its endogenous nature — your body already makes GHK. |
| Key Limitations | Most evidence comes from a single research group (Sikiric et al.). Human clinical trials are in early stages. No large randomized controlled trials yet. | Research is fragmented across different formulations and delivery methods. Topical vs injectable produces very different bioavailability. Limited standardized clinical data. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
BPC-157
Promotes blood vessel growth (angiogenesis), upregulates growth factor expression including VEGF and EGF, and modulates nitric oxide pathways. Think of it as a signal that tells damaged tissue to start rebuilding its blood supply and repair infrastructure.
GHK-Cu
Binds copper ions and delivers them to tissue, activating fibroblasts — the cells that build collagen and elastin. Also stimulates antioxidant enzymes and tissue remodeling pathways. Think of it as a repair signal specifically tuned for the scaffolding that holds skin together.
BPC-157 works from the inside out. It targets the blood supply and growth factor signaling that drives deep tissue repair — tendons, gut, muscles. GHK-Cu works from the outside in. It activates the fibroblasts and collagen pathways that rebuild skin structure. They target different biological layers. BPC-157 is about vascular repair and tissue regeneration. GHK-Cu is about structural protein synthesis and skin biology.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 398 indexed studies. Here are the key findings.
BPC-157 sits at L3 with over 200 published studies including human pilot data. GHK-Cu sits at L2 with well-characterized in vitro mechanisms but less clinical validation. BPC-157 has deeper research from systematic animal programs. GHK-Cu has broader but more scattered research across cosmetic and wound healing applications.
For tendon, ligament, or gut repair research — BPC-157 has significantly more relevant published data.
For skin rejuvenation, collagen support, or topical wound healing — GHK-Cu is more directly studied for these applications.
For deep tissue injury recovery — BPC-157 has the stronger preclinical evidence base.
For anti-aging skin protocols — GHK-Cu is the more targeted compound.
Key Limitations
- •Direct head-to-head comparison studies do not exist.
- •BPC-157 research is heavily concentrated in one research group.
- •GHK-Cu research spans many formulations, making cross-study comparison difficult.
- •Neither compound has completed Phase III clinical trials.
PSI Verdict
SUPPORTED BY EVIDENCE
BPC-157 has more published research for deep tissue repair, with over 200 studies and human pilot data. GHK-Cu has well-characterized mechanisms for skin biology and collagen stimulation. Both show consistent results within their respective research domains.
NOT YET ESTABLISHED
No head-to-head comparison exists. We do not know whether combining them produces additive effects. Long-term human safety data is incomplete for both compounds.
CONFIDENCE LEVEL
Moderate for both, within their respective applications. BPC-157 has more clinical depth for tissue repair. GHK-Cu has solid mechanistic evidence for skin. Using the wrong one for the wrong application means you are relying on research that was not designed for your question.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"Insufficient evidence
GHK-Cu
"GHK-Cu is the best anti-aging peptide for skin"Plausible but unproven
"It regrew my hair"Anecdotal only
"Topical is just as effective as injections"Anecdotal only
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
BPC-157
Extensive animal safety data with no reported toxicity at therapeutic doses. Two human pilot studies published (2024-2025) with no serious adverse events. Not FDA-approved.
GHK-Cu
Well-tolerated in topical applications. Limited safety data for injectable use. Generally considered low-risk based on its endogenous nature — your body already makes GHK.
Both are considered generally well-tolerated. BPC-157 has extensive animal toxicology data and two human pilot studies. GHK-Cu is endogenous (your body makes it naturally), which gives it a favorable theoretical safety profile, but injectable safety data is limited. Neither is FDA-approved for any indication.
WHAT THE RESEARCH SUGGESTS
These are different tools for different jobs. Comparing them is like comparing a plumber and an electrician — both fix things, but in completely different systems. BPC-157 for internal tissue repair. GHK-Cu for skin and collagen biology.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.